HEARTS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Cardiovascular Imaging

Transcription

1 Author Listing of Comprehensive Relationships With Industry and Other Entities for the ACCF/AHA/ASE/ASNC/HRS/IAC/MENDED HEARTS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Imaging Committee Member Daniel B. Mark (Chair) Employment Consultant Speaker s Bureau Duke Clinical Research Ownership/ Partnership/ Principal Personal Research Janssen AstraZeneca* Gilead Pharma Medtronic Institutional, Organizational or Other Financial Benefit Agency for Healthcare Research & Quality Medtronic National Health Expert Witness Jeffrey L. Anderson Intermountain Chief of GlaxoSmithKline AstraZeneca Gilead Pharma Thrombolysis In Myocardial Infarction Study Group-48, 51, 52, and 54 Toshiba Intermountain Health Care Harvard Janssen (Data Safety Monitoring Board) Washington National Health ICON Clinical Research Jeffrey A. Brinker Johns Hopkins Hospital Care Core *

2 James M. Brophy Donald E. Casey Jr. Russell R. Cross Daniel Edmundowicz Rory Hachamovitch and McGill Hospital Centre, Royal Victoria Hospital & Epidemiology Atlantic Health Vice President of Quality, Chief Medical Officer Children s National Medical Center Director Quality and Outcomes Program of Pittsburgh, Section Chief of Cleveland Clinic Staff Cardiologist, Section of Imaging, Department of 2011 Defendant, Canadian Patent Case 2007 Plaintiff, Vioxx Litigation GNC Corporation Merck/Schering Plough GE Healthcare

3 Mark A. Hlatky Jill E. Jacobs Stanford School of Health Research & Policy, NYU Langone Blue Cross Blue Shield Association Technology Assessment Committee Genentech Gilead American College of Association Expert Reviewer for Consumers Union North American Society of Imaging Suzette Jaskie West Michigan Heart, P.C. Chief Executive Officer MedAxiom Medtronic Boston Scientific MedAxiom Kevin G. Kett Vinay Malhotra Frederick A. Masoudi s of Waterbury Medical Director Cardiac Study Center Director, Cardiac Catheterization Laboratory of Colorado, Denver, Division of Agency for Healthcare Research & Quality American College of Association Massachusetts Medical Society Oklahoma Foundation for 2012 Plaintiff, Acute Coronary Syndrome

4 Michael V. McConnell Stanford and Co- Director Noninvasive Imaging Section, Division of Association CoRepair Kowa Pharmaceuticals National Health Medical Quality GE Healthcare Geoffrey D. Rubin Leslee J. Shaw M. Eugene Sherman Steve Stanko Duke George B. Geller Professor and Chairman, Department of Emory School of Aurora Medical s P.C./ of Colorado Denver School of President; Clinical Professor of Mended Hearts, Inc Cath Patient Outreach Chair Fovia HeartFlow Informatics in Context Terarecon Lung, and Blood Patient Centered Outcomes Research Bristol Myers Squibb Pfizer Astellas Pharma Bracco Diagnostics AstraZeneca Arca Biopharrma 2009 Defendant, X- ray Interpretation 2009 Plaintiff, X- ray Interpretation Bristol Meyers Squibb Heart Failure Society of America* Hospital Corporation of America R. Parker Ward of

5 Chicago Medical Center This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees. *Significant relationship. No financial benefit.